SREBF1 and breast carcinoma: Through RNA sequencing, western blots, IHC, and fluorescence microscopy it was demonstrated that withaferin’s efficacy is associated with reduced lipogenesis in breast cancer cells and mammary tumors, through suppressing precursor and mature forms of SREBP1 [138].